Detalles de la búsqueda
1.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study.
J Clin Pharmacol
; 2023 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37772436
2.
A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a 14 C-Microtracer Approach.
Clin Pharmacol Drug Dev
; 11(7): 815-825, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35506501
3.
The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.
Arthritis Rheumatol
; 73(12): 2206-2218, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34423919
4.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
Arthritis Res Ther
; 21(1): 269, 2019 12 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31805989
Resultados
1 -
4
de 4
1
Próxima >
>>